News related to Fenoglide (Fenofibrate) and/or conditions it is approved for
ACCORD Lipid Study Brings New Hope To People With Type 2 Diabetes And Atherogenic Dyslipidemia Says International Academic Foundation
Source: Cardiovascular / Cardiology News From Medical News Today [2010.03.17]
Cardiovascular risk can be reduced by an additional 31 percent in type 2 diabetes patients with atherogenic dyslipidemia, the common combination of elevated triglycerides (TG, 204 mg/dL or 2.3 mmol/L or higher) and low levels of high-density lipoprotein cholesterol (HDL-C, 34 mg/dL or 0.88 mmol/L or lower). This is achieved by adding fenofibrate to simvastatin...
Impax Laboratories Confirms Patent Challenge Relating To TRILIPIX(R) Delayed-Release Capsules, 135 Mg And 45 Mg
Source: Cholesterol News From Medical News Today [2010.03.17]
Impax Laboratories, Inc. (NASDAQ: IPXL) confirms that it has initiated a challenge of the patent listed by Abbott Laboratories and Fournier Laboratories Ireland Ltd. in connection with its TRILIPIX® (choline fenofibrate) delayed-release capsules, 135 mg and 45 mg...
|
